[Multiple myeloma].
Multiple myeloma causes debilitating clinical symptoms including intractable bone pain, disabling multiple fractures and hypercalcemia. Bisphosphonates, potent inhibitors of osteoclast-mediated bone destruction, prevent skeletal-related events in myeloma. However, the impact of long-term bisphosphonate use remains unclear because of insufficient follow-up, while osteonecrosis of the jaw (ONJ) emerges as a major concern. The proteosome inhibitor bortezomib is a novel anti-myeloma agent, which has been recently drawn a considerable attention in its anabolic effects to resume bone formation in patients with myeloma. It is important to clarify the roles of these bone-targeting agents in the treatment for a myeloma bone disease and make the best use of them by eliminating underlying risk of their adverse effects.
Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine.
Masahiro
M
Abe
D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000209:etiology*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use*; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy / Q000209:etiology; D007571:Jaw Diseases / Q000139:chemically induced; D009101:Multiple Myeloma / Q000150:complications* / Q000188:drug therapy*; D010020:Osteonecrosis / Q000139:chemically induced; D011480:Protease Inhibitors / Q000627:therapeutic use*; D011719:Pyrazines / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D001897:Boronic Acids; D004164:Diphosphonates; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib